Anna L. Goodman

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2020 · 5K citations · Full text

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2021 · 1.2K citations · Full text

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Cristina Menni, Kerstin Kläser, Anna May et al. · The Lancet Infectious Diseases · 2021 · 1.1K citations · Full text

Vaccination, Vaccine Side-effects, Preventive Medicine +9

Correction: Corrigendum: The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody

Alexander D. Douglas, Andrew R. Williams, Joseph J. Illingworth et al. · Nature Communications · 2013 · 924 citations · Full text

Vaccination, Pathogenesis, Immunology +3

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley et al. · The Lancet · 2021 · 649 citations · Full text